Novo Nordisk (NYSE:NVO) is scheduled to report earnings on November 2 before the opening bell
The Street consensus for Novo Nordisk (NYSE:NVO) is earnings of $0.71 per share on revenue of $7.91 billion, compared to $0.90 per share on revenue of $6.47 billion a year earlier.
Ozempic has seen a huge surge in sales, leading the company to increase its annual sales growth guidance earlier this month.
Novo Nordisk (NYSE:NVO) now expects sales growth between 32% and 38% and an EBIT (earnings before interest and taxes) surge of 40% to 46%, above previous expectations of 27% and 33%, and 31% and 37%, respectively.
In fact, Novo Nordisk’s sales increased by 33% and operating profit increased by 37% in the first nine months of 2023.
Shares of Novo Nordisk traded near flat Mondy morning at $97.18.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel